These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 18560222

  • 1. Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
    Nagai S, Takenaka K, Sonobe M, Wada H, Tanaka F.
    Chemotherapy; 2008; 54(3):166-75. PubMed ID: 18560222
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
    Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G, Peters GJ.
    Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells.
    Wouters A, Pauwels B, Lardon F, Pattyn GG, Lambrechts HA, Baay M, Meijnders P, Vermorken JB.
    BMC Cancer; 2010 Aug 19; 10():441. PubMed ID: 20723210
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In Vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines.
    Tesei A, Ricotti L, De Paola F, Amadori D, Frassineti GL, Zoli W.
    Clin Cancer Res; 2002 Jan 19; 8(1):233-9. PubMed ID: 11801564
    [Abstract] [Full Text] [Related]

  • 11. Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells.
    Leon LG, Gemelli M, Sciarrillo R, Avan A, Funel N, Giovannetti E.
    Curr Drug Targets; 2014 Jan 19; 15(14):1331-40. PubMed ID: 25483224
    [Abstract] [Full Text] [Related]

  • 12. Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.
    Nagai H, Yasuda H, Hatachi Y, Xue D, Sasaki T, Yamaya M, Sakamori Y, Togashi Y, Masago K, Ito I, Kim YH, Mio T, Mishima M.
    Int J Oncol; 2012 Jul 19; 41(1):24-30. PubMed ID: 22552400
    [Abstract] [Full Text] [Related]

  • 13. Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.
    Lustgarten DE, Deshpande C, Aggarwal C, Wang LC, Saloura V, Vachani A, Wang LP, Litzky L, Feldman M, Creaney J, Nowak AK, Langer C, Inghilleri S, Stella G, Albelda SM.
    J Thorac Oncol; 2013 Apr 19; 8(4):469-77. PubMed ID: 23486267
    [Abstract] [Full Text] [Related]

  • 14. Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
    Giovannetti E, Zucali PA, Assaraf YG, Leon LG, Smid K, Alecci C, Giancola F, Destro A, Gianoncelli L, Lorenzi E, Roncalli M, Santoro A, Peters GJ.
    Br J Cancer; 2011 Nov 08; 105(10):1542-53. PubMed ID: 21970874
    [Abstract] [Full Text] [Related]

  • 15. Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.
    Christoph DC, Asuncion BR, Mascaux C, Tran C, Lu X, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Neumann V, Hepp R, Welter S, Stamatis G, Tannapfel A, Schuler M, Eberhardt WE, Hirsch FR.
    J Thorac Oncol; 2012 Sep 08; 7(9):1440-8. PubMed ID: 22895141
    [Abstract] [Full Text] [Related]

  • 16. Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation.
    Cameron RB, Hou D.
    J Thorac Cardiovasc Surg; 2013 Feb 08; 145(2):496-504. PubMed ID: 23174177
    [Abstract] [Full Text] [Related]

  • 17. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
    Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M.
    Clin Cancer Res; 2004 May 01; 10(9):2936-43. PubMed ID: 15131028
    [Abstract] [Full Text] [Related]

  • 18. Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
    Grønberg BH, Lund-Iversen M, Strøm EH, Brustugun OT, Scott H.
    J Thorac Oncol; 2013 Oct 01; 8(10):1255-64. PubMed ID: 24457236
    [Abstract] [Full Text] [Related]

  • 19. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
    Yamamoto K, Seike M, Takeuchi S, Soeno C, Miyanaga A, Noro R, Minegishi Y, Kubota K, Gemma A.
    Oncol Rep; 2014 Dec 01; 32(6):2365-72. PubMed ID: 25231602
    [Abstract] [Full Text] [Related]

  • 20. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.
    Cioce M, Ganci F, Canu V, Sacconi A, Mori F, Canino C, Korita E, Casini B, Alessandrini G, Cambria A, Carosi MA, Blandino R, Panebianco V, Facciolo F, Visca P, Volinia S, Muti P, Strano S, Croce CM, Pass HI, Blandino G.
    Oncogene; 2014 Nov 13; 33(46):5319-31. PubMed ID: 24240684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.